Arrayit Corporation (OTC Bulletin Board: ARYC), a life sciences and healthcare technology leader, announced today that the Company has received patent protection in the State of Israel for its proprietary Variation Identification Platform™ (VIP™) DNA testing technology. The Israeli patent extends Arrayit's current patent portfolio, which includes VIP patents in the United States, Singapore, New Zealand, China, South Korea, and the European Union.
Israeli Patent Number 153848 empowers Arrayit to develop and commercialize economical diagnostic tests for important medical conditions including human diseases. The VIP approach uses microarrays, which are diagnostic devices that contain thousands of patient samples printed as microscopic spots on a glass substrate. One VIP microarray can test up to 80,000 patient samples simultaneously, using miniaturization, automation and massively parallel VIP devices to acquire the medical information. Improved testing speed, accuracy and healthcare cost reductions are among the benefits of testing many patients at once.
Arrayit Corporation CEO, Rene Schena, stated, "We are pleased to obtain patent protection for our VIP technology in Israel. This important achievement adds to our already expansive intellectual property portfolio and will empower us to aggressively pursue new growth opportunities for our VIP products and services in this important region."
Regular late-life exercise has a beneficial impact on DNA damage and telomere dysfunction